Get started
Akebia Therapeutics, Inc.Akebia Therapeutics, Inc.Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

AKBA trade ideas

Akebia Therapeutics trade setupEntry level $4.41 = target price $5.14 Average analysts price target $14.86 | Buy Company profile Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
NASDAQ:AKBALong
by Bullishcharts
1
AKBA - Flag formation Momentum Long from $15.60 & $15 Oct Calls AKBA had a good upward run forming a fallen angel formation, and now after some consolidation it seems getting ready for a second run.It has a fair amount of insider buying going on. We think it has very good upside potential if it can break around $16.60. To play this we would consider October $15 calls, which are $1.45/$1.75 * Trade Criteria * Date First Found- August 24, 2017 (Intraday Alert) Pattern/Why- Flag formation; Fallen angel formation continuation. Entry Target Criteria- At current label ($15.60) (Hti August 24, 2017) Exit Target Criteria- Momentum Stop Loss Criteria- $ 14.63 Please check back for Trade updates. (Note: Trade update is little delayed here.)
NASDAQ:AKBALong
by AcornWealthCorp